APA (7th ed.) Citation

Macha, S., Mattheus, M., Halabi, A., Pinnetti, S., Woerle, H. J., & Broedl, U. C. (2014). Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes, obesity & metabolism, 16(3), 215-222. https://doi.org/10.1111/dom.12182

Chicago Style (17th ed.) Citation

Macha, S., M. Mattheus, A. Halabi, S. Pinnetti, H. J. Woerle, and U. C. Broedl. "Pharmacokinetics, Pharmacodynamics and Safety of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Subjects with Renal Impairment." Diabetes, Obesity & Metabolism 16, no. 3 (2014): 215-222. https://doi.org/10.1111/dom.12182.

MLA (9th ed.) Citation

Macha, S., et al. "Pharmacokinetics, Pharmacodynamics and Safety of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Subjects with Renal Impairment." Diabetes, Obesity & Metabolism, vol. 16, no. 3, 2014, pp. 215-222, https://doi.org/10.1111/dom.12182.